Compare Sanofi SA (SNY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs T Rowe Price Group Inc — how do they compare? Sanofi SA trades at $43.12 (market cap $103.41B), while T Rowe Price Group Inc trades at $107.71 (market cap $22.98B). The key difference: Sanofi SA is far larger — about 4.5× T Rowe Price Group Inc's market cap, and Sanofi SA pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| SNY | TROW | |
|---|---|---|
Market Cap | $103.41B | $22.98B |
Sector | Health | Financials |
52-Week High | $52.34 | $121.68 |
52-Week Low | $41.33 | $86.19 |
Enterprise Value | $123.44B | $20.18B |
Dividend Yield | 5.65% | 4.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal and key support at $109. The stock shows strong profitability with a net margin of 29.26% and ROE of 20.1%, supported by recent earnings beats in Q1 and Q2 2026. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and ongoing AI adoption, positioning the firm for growth amid equity outflows.
The outlook is mixed: valuation metrics like a P/E of 10.99 suggest potential upside to the $111.67 consensus target, but bearish technicals and analyst caution (63% hold rating) indicate near-term headwinds. Risks include market-sensitive revenue and competitive pressures, though dividend stability and institutional buying support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
